SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Derivatives

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: RWReeves who wrote (391)9/15/1999 4:47:00 PM
From: LLCF  Read Replies (2) of 555
 
Further response:

<(there will never be a tender) without Genzyme spinning it off or getting bought out itself?>

IMO this is the essence of the difference, it won't get sold unless 'general' wants to sell... and therefore you can't force management to do things that may be possible in other companies by resting control.

The rest of this is the same as any other company:

< And we can't get at the doggone cash flows because it won't come out a as a dividend.>

<The Retained Earnings are only of value if you can somehow get at them- At least in my experience, companies that retain 'em don't always do so for the best interest of the shareholders and that's when the shareholders have to be able to vote and say , "Thanks, No" in a variety of ways.>

< has been claimed to trade at about 1/2 to 2/3 of real value simply because of the lack of voting rights->

IM experience your concern usually comes up with high cash flow companies where some raider from florida has purchased a controlling interest and is sucking the cash out into his boats and condo's while leaving the minority shareholders to suck wind and try to sue. Hardly the case here, the company absolutely cannot legally take any more than their alotted share of cashflows, etc.

DAK

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext